Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04073615 · ClinicalTrials.gov registry record · Phase 1
A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)
A Phase 1 study, sponsored by Elevar Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT04073615: Clinical Trial Phase 1 study, sponsored by Elevar Therapeutics.
NCT04073615 is a Phase 1 study that was terminated before completion, run by Elevar Therapeutics. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04073615, a Phase 1 study, was terminated before completion, sponsored by Elevar Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in participants with mCRC.
Interventions
- DRUG Trifluridine/Tipiracil
- DRUG Rivoceranib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 1 |
Why NCT04073615 stopped before completion
NCT04073615 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 0 conditions, and to 2 interventions - of which Trifluridine/Tipiracil is the first listed.
NCT04073615 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04073615 about?
NCT04073615 is a clinical study titled "A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)". The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in participants with mCRC.
What is the current status of trial NCT04073615?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2019-11-18. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT04073615?
The interventions under investigation include: Trifluridine/Tipiracil (DRUG), Rivoceranib (DRUG).
Who is sponsoring clinical trial NCT04073615?
This trial is sponsored by Elevar Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04073615's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI